Roche and the Spanish Lung Cancer Group (SLCG) will collaborate on the first Phase III trial to investigate Tarceva in lung cancer patients with genetic mutations in their epidermal growth factor receptor (EGFR). Over activity of EGFR is associated with the growth and development of lung cancer. It has been demonstrated that all patients who do not have the mutations (called ‘wild type’) benefit from Tarceva, which is approved for patients with locally advanced or metastatic non-s...